Purpose: To investigate the effects of various prostate biopsy protocols with reduced cores on the detection of clinically significant prostate cancer (csPCa) in individuals with MRI-visible lesions (Prostate Imaging Reporting and Data System ≥ 3).
Methods: A total of 464 patients with MRI-visible lesions were recruited. All patients underwent two or more targeted biopsies (TB) and systematic biopsies (SB). Several hypothetical biopsy schemes were set-up: TB alone, TB+ipsilateral SB, TB+contralateral SB, TB+SB of the targeted sector (TB+t-SB), and TB+SB of the non-targeted sector (TB+n-SB). A subgroup analysis of patients with multiple MRI-visible lesions was performed. The standard of reference was defined as TB+SB. McNemar test was used to compare csPCa detection rates between various sampling schemes.
Results: The detection rates for prostate cancer and csPCa were 72.8% (338 of 464) and 62.1% (288 of 464), respectively. There were 8.0%, 0.3%, 6.3%, 1.0%, and 4.5% cases in which TB alone, TB+ipsilateral SB, TB+contralateral SB, TB+t-SB, and TB+n-SB would have missed csPCa, respectively. All hypothetical schemes, with the exception of TB+contralateral SB (p = 0.063), significantly outperformed TB alone in terms of csPCa detection (p < 0.05). As for the multi-focus cohort, which included 48 cases, none of the non-index lesions had a higher Gleason grade than the index lesions within the same patients.
Conclusion: TB+ipsilateral SB might be the optimal biopsy scheme for detecting csPCa. As for the multi-focus cohort, the biopsy of the non-index lesions provided limited pathological information.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00261-023-03894-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.
Brachytherapy
January 2025
Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: To determine outcomes of MRI-assisted radiosurgery (MARS) for salvage brachytherapy using the radioisotope Pd after various upfront treatments including surgery, external beam radiotherapy, and brachytherapy.
Methods: We retrospectively reviewed data for patients who underwent salvage MARS for intraprostatic lesions or prostate bed recurrences from 2016 to 2022. Biochemical recurrence, prostate cancer-specific, and overall survival, and the cumulative incidences of toxicities, were determined by Kaplan-Meier estimates.
Transperineal 3D fusion imaging-guided targeted microwaves ablation for low to intermediate-risk prostate cancer: results of a phase I-II study.
Minim Invasive Ther Allied Technol
November 2024
Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, Turin, Italy.
Article Synopsis
- Targeted microwave ablation (TMA) shows promise as a safe and effective treatment for localized prostate cancer, based on a pilot trial involving 11 patients.* -
- No severe complications were reported, and a significant percentage of patients exhibited no cancer in the treated area after follow-up, although new cancer foci were found in some cases.* -
- The study acknowledges limitations such as a small sample size, short follow-up duration, and absence of a comparison group, but supports the potential of TMA combined with fusion imaging for prostate cancer therapy.*
Imaging blood-brain barrier dysfunction in drug-resistant epilepsy: A multi-center feasibility study.
Epilepsia
January 2025
Department of Neurology, Rabin Medical Center, Beilinson Hospital and Tel-Aviv University, Petah Tikva, Israel.
Objective: Blood-brain barrier dysfunction (BBBD) has been linked to various neurological disorders, including epilepsy. This study aims to utilize dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to identify and compare brain regions with BBBD in patients with epilepsy (PWE) and healthy individuals.
Methods: We scanned 50 drug-resistant epilepsy (DRE) patients and 58 control participants from four global specialized epilepsy centers using DCE-MRI.
Regional Versus Systematic Biopsy in Addition to Targeted Biopsy: Results from a Systematic Review and Meta-analysis.
Eur Urol Oncol
October 2024
Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, UK.
Article Synopsis
- The study compares the effectiveness of targeted biopsy plus regional biopsy (TBx + RBx) against the standard approach of targeted biopsy plus systematic biopsy (TBx + SBx) in detecting clinically significant prostate cancer.
- A meta-analysis of 21 studies showed that TBx + RBx had a similar detection yield of significant prostate cancer compared to TBx + SBx, suggesting that RBx can replace some systematic biopsies.
- The study identifies limitations such as the retrospective nature of the included studies and variability in how regional biopsy was defined, but overall supports using TBx + RBx for prostate cancer detection.
Objective: The objective of this study is to compare detection rates of extracapsular extension (ECE) of prostate cancer (PCa) using artificial intelligence (AI)-generated cancer maps versus MRI and conventional nomograms.
Materials And Methods: We retrospectively analysed data from 147 patients who received MRI-targeted biopsy and subsequent radical prostatectomy between September 2016 and May 2022. AI-based software cleared by the United States Food and Drug Administration (Unfold AI, Avenda Health) was used to map 3D cancer probability and estimate ECE risk.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!